Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced the engagement of Donohoe Advisory Associates LLC (“Donohoe”) for consulting and advisory services in connection with the potential up-listing of Silo’s common shares on the NASDAQ Stock Market.

Source

Previous articlePsyched Wellness Hires Del Mahabadi as Digital Marketing Consultant to Drive AME-1 Product Launch
Next articlePharmaTher Announces Positive Research Results for LSD Microneedle Patch